CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹5,273 Cr | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr |
What is the latest Consolidated Net Profit of CIPLA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2026 | ₹5,273 Cr |
| Mar2025 | ₹4,122 Cr |
| Mar2024 | ₹2,802 Cr |
| Mar2023 | ₹2,517 Cr |
| Mar2022 | ₹2,405 Cr |
How is Consolidated Net Profit of CIPLA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,273 Cr | 27.93 | |
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | - | |
Compare Consolidated Net Profit of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹112,879.8 Cr | 2.4% | -1.1% | -12.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹444,717.0 Cr | 1% | -3.3% | 13.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹255,115.0 Cr | 2.6% | 10.8% | 57.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,613.0 Cr | 2.7% | 0.3% | 39.6% | Stock Analytics | |
| MANKIND PHARMA | ₹102,247.0 Cr | 6.8% | 4.6% | -6.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,395.0 Cr | 2.5% | 0.8% | -8.5% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 2.4% |
-1.1% |
-12.6% |
| SENSEX | -0.5% |
-4.8% |
-11% |
You may also like the below Video Courses